Erratum to: Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer [Supportive Care in Cancer, (2015), DOI:10.1007/s00520-015-2904-5];Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer

Supportive Care in Cancer

Volumn 24, Issue 1, 2016, Pages 447-455

  Stopeck, Alison T ^a   Fizazi, Karim ^b   Body, Jean Jacques ^c   Brown, Janet E ^d,e   Carducci, Michael ^f   Diel, Ingo ^g   Fujiwara, Yasuhiro ^h   Martín, Miguel ⁱ   Paterson, Alexander ^j   Tonkin, Katia ^k   Shore, Neal ^l   Sieber, Paul ^m   Kueppers, Frank ⁿ   Karsh, Lawrence ^o   Yardley, Denise ^p   Wang, Huei ^q   Maniar, Tapan ^q   Arellano, Jorge ^q   Braun, Ada ^q  

^a UNIVERSITY OF ARIZONA   (United States)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c BRUGMANN UNIVERSITY HOSPITAL   (Belgium)

^d ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^e UNIVERSITY OF SHEFFIELD   (United Kingdom)

^f JOHNS HOPKINS UNIVERSITY   (United States)

^g Institute for Gynecologic Oncology   (Germany)

^h NATIONAL CANCER CENTER HOSPITAL   (Japan)

ⁱ UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^j TOM BAKER CANCER CENTRE   (Canada)

^k CROSS CANCER INSTITUTE   (Canada)

^l Carolina Urologic Research Center   (United States)

^m Urological Associates of Lancaster   (United States)

ⁿ Urology Associates   (New Zealand)

^o Urology Center of Colorado   (United States)

^p SARAH CANNON RESEARCH INSTITUTE   (United States)

^q AMGEN INC   (United States)

more..

Author keywords

Bone metastases; Breast cancer; Denosumab; Osteonecrosis of the jaw; Prostate cancer; Zoledronic acid

Indexed keywords

DENOSUMAB; PLACEBO; ZOLEDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; IMIDAZOLE DERIVATIVE; MONOCLONAL ANTIBODY;

AGED; ANEMIA; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; BONE METASTASIS; BREAST CANCER; CANCER PATIENT; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FATIGUE; FEMALE; HUMAN; HYPOCALCEMIA; INFECTION; INFLUENZA; JAW OSTEONECROSIS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NAUSEA; OPEN STUDY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RHINOPHARYNGITIS; TREATMENT DURATION; URINARY TRACT INFECTION; BONE NEOPLASMS; BREAST TUMOR; CLINICAL TRIAL; CONTROLLED STUDY; CUTANEOUS DRUG ADMINISTRATION; DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; PROSTATE TUMOR; RANDOMIZED CONTROLLED TRIAL; SECONDARY; TREATMENT OUTCOME;

ADMINISTRATION, CUTANEOUS; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BREAST NEOPLASMS; DENOSUMAB; DIPHOSPHONATES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMIDAZOLES; INFUSIONS, INTRAVENOUS; LONG-TERM CARE; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 84949085967     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-015-2985-1     Document Type: Erratum

References (29)

1. Kris MG, Benowitz SI, Adams S, Diller L, Ganz P, Kahlenberg MS, Le QT, Markman M, Masters GA, Newman L, Obel JC, Seidman AD, Smith SM, Vogelzang N, Petrelli NJ (2010) Clinical cancer advances 2010: annual report on progress against cancer from the American society of clinical oncology. J Clin Oncol 28:5327–5347
2. Lipton A, Fizazi K, Stopeck AT, Henry DH, Brown JE, Yardley DA, Richardson GE, Siena S, Maroto P, Clemens M, Bilynskyy B, Charu V, Beuzeboc P, Rader M, Viniegra M, Saad F, Ke C, Braun A, Jun S (2012) Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer 48:3082–3092
3. Fizazi K, Carducci M, Smith M, Damiao R, Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H, Jiang Q, Tadros S, Dansey R, Goessl C (2011) Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377:813–822
4. Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, Lichinitser M, Fujiwara Y, Yardley DA, Viniegra M, Fan M, Jiang Q, Dansey R, Jun S, Braun A (2010) Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 28:5132–5139
5. Fallowfield L, Cleeland CS, Body JJ, Stopeck A, von Moos R, Patrick DL, Clemons M, Tonkin K, Masuda N, Lipton A, de Boer R, Salvagni S, Oliveira CT, Ying W, Braun A, Cong Z (2011) Pain severity and analgesic use associated with skeletal-related events in patients with advanced breast cancer and bone metastases. Cancer Res 71(Suppl 3):Abstract P4-13–01
6. Coleman RE (2001) Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 27:165–176
7. Tchekmedyian NS, Chen YM, Saad F (2010) Disease progression increases the risk of skeletal-related events in patients with bone metastases from castration-resistant prostate cancer, lung cancer, or other solid tumors. Cancer Investig 28:849–855
8. Chang ST, Tenforde AS, Grimsrud CD, O’Ryan FS, Gonzalez JR, Baer DM, Chandra M, Lo JC (2012) Atypical femur fractures among breast cancer and multiple myeloma patients receiving intravenous bisphosphonate therapy. Bone 51:524–527
9. Dunstan CR, Felsenberg D, Seibel MJ (2007) Therapy insight: the risks and benefits of bisphosphonates for the treatment of tumor-induced bone disease. Nat Clin Pract Oncol 4:42–55
10. Amadori D, Aglietta M, Alessi B, Gianni L, Ibrahim T, Farina G, Gaion F, Bertoldo F, Santini D, Rondena R, Bogani P, Ripamonti CI (2013) Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial. Lancet Oncol 14:663–670
11. Coleman RE, Wright J, Houston S, Agrawal R, Purohit OP-K, Hayward L, Simmonds P, Waterhouse A, Marshall H, BISMARK Investigators (2012) Randomized trial of marker-directed versus standard schedule zoledronic acid for bone metastases from breast cancer. J Clin Oncol 30(Suppl):Abstract 511
12. Hoff AO, Toth BB, Altundag K, Johnson MM, Warneke CL, Hu M, Nooka A, Sayegh G, Guarneri V, Desrouleaux K, Cui J, Adamus A, Gagel RF, Hortobagyi GN (2008) Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 23:826–836
13. Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Bhoomi M, O’Ryan F (2014) American association of oral and maxillofacial surgeons position paper on medication-related osteonecrosis of the jaw—2014 update. J Oral Maxillofac Surg 72:1938–1956
14. Hortobagyi G, Lipton A, Chew H, Gradishar W, Sauter N, Mohanlal R, Zheng M, McGrain B, Van Poznak C (2014) Efficacy and safety of continued zoledronic acid every 4 weeks versus every 12 weeks in women with bone metastases from breast cancer: results of the optimize-2 trial. J Clin Oncol 32(Suppl):Abstract LBA9500
15. Cancer and Leukemia Group B (2012) Zoledronic acid in treating patients with metastatic breast cancer, metastatic prostate cancer, or multiple myeloma with bone involvement. ClinicalTrials.gov. http://clinicaltrials.gov/show/NCT00869206. Accessed 01 December 2014
16. Doshi S, Sutjandra L, Zheng J, Sohn W, Peterson M, Jang G, Chow AT, Perez-Ruixo JJ (2012) Denosumab dose selection for patients with bone metastases from solid tumors. Clin Cancer Res 18:2648–2657
17. Russell RG, Watts NB, Ebetino FH, Rogers MJ (2008) Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 19:733–759
18. Fizazi K, Lipton A, Mariette X, Body JJ, Rahim Y, Gralow JR, Gao G, Wu L, Sohn W, Jun S (2009) Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol 27:1564–1571
19. Gedmintas L, Solomon D, Kim S (2013) Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: a systematic review and meta-analysis. J Bone Miner Res 28:1729–1737
20. Paparodis R, Buehring B, Pelley E, Binkley N (2013) A case of an unusual subtrochanteric fracture in a patient receiving denosumab. Endocr Pract 19:e64–e68
21. XGEVA® (denosumab) US Package Insert (2014) Amgen Inc. Thousand Oaks, CA
22. Saad F, Brown JE, Van Poznak C, Ibrahim T, Stemmer SM, Stopeck AT, Diel IJ, Takahashi S, Shore N, Henry DH, Barrios CH, Facon T, Senecal F, Fizazi K, Zhou L, Daniels A, Carriere P, Dansey R (2012) Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol 23:1341–1347
23. Smith MR, Saad F, Coleman R, Shore N, Fizazi K, Tombal B, Miller K, Sieber P, Karsh L, Damiao R, Tammela TL, Egerdie B, Van Poppel H, Chin J, Morote J, Gomez-Veiga F, Borkowski T, Ye Z, Kupic A, Dansey R, Goessl C (2012) Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet 379:39–46
24. Smith MR, Saad F, Oudard S, Shore N, Fizazi K, Sieber P, Tombal B, Damiao R, Marx G, Miller K, Van Veldhuizen P, Morote J, Ye Z, Dansey R, Goessl C (2013) Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time. J Clin Oncol 31:3800–3806
25. Rosen LS, Gordon D, Tchekmedyian NS, Yanagihara R, Hirsh V, Krzakowski M, Pawlicki M, De Souza P, Zheng M, Urbanowitz G, Reitsma D, Seaman J (2004) Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer 100:2613–2621
26. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Zheng M, Zoledronic Acid Prostate Cancer Study Group (2004) Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96:879–882
27. Brufsky AM, Sereika SM, Mathew A, Tomifumi O, Singh V, Rosenzweig M (2013) Long-term treatment with intravenous bisphosphonates in metastatic breast cancer: a retrospective study. Breast J 19:504–511
28. Block GA, Bone HG, Fang L, Lee E, Padhi D (2012) A single-dose study of denosumab in patients with various degrees of renal impairment. J Bone Miner Res 27:1471–1479
29. Body JJ, Lipton A, Gralow J, Steger GG, Gao G, Yeh H, Fizazi K (2010) Effects of denosumab in patients with bone metastases with and without previous bisphosphonate exposure. J Bone Miner Res 25:440–446